Thomas A. Collet
President
Medicine
Medicine
United States of America
Biography
Thomas A. Collet is a serial entrepreneur, whose companies have raised more than $35 million in seed and early stage capital. Rubicon Genomics, his first start-up, continues to grow rapidly in the genomic sample prep space. Neural Intervention Technologies, a company that he co-founded and that developed a product for hemorrhagic stroke, was sold to W.L. Gore in 2006. ProNAi Therapeutics, a cancer therapy company where he was the first CEO, filed to go public in 2015. Earlier, Collet was a general partner at Tullis-Dickerson, helping manage a $40 million seed and early stage fund. He also was a vice president at Monsanto, where he helped start Integrated Protein Technologies, the company’s internal venture for the production of pharmaceutical proteins in green plants. He began his career at McKinsey, working with clients in technology-focused business units of Fortune 500 companies. Degrees: Ph.D., Massachusetts Institute of Technology; postdoctoral fellow, Scripps Research Institute, La Jolla, CA.
Research Interest
Medical and Diaganostic techniques
